Clinicians managing advanced prostate cancer are increasingly shifting from age-based protocols to nuanced, biomarker-driven treatment sequences.
Following a September 2026 workshop held by OncLive, experts are discussing how to balance the use of androgen receptor pathway inhibitors, chemotherapy triplets, and radioligand therapies in patients with metastatic disease.
Translating Treatment Decisions for Patients
- Genomic Precision: Doctors now use genetic markers to identify which patients will respond best to specific combinations, rather than relying solely on age or standard hormone therapy.
- Managing Toxicity: Because aggressive treatments like chemotherapy and radioligand therapy carry risks to bone marrow and overall health, clinicians are carefully timing these interventions to preserve quality of life.
- Personalized Sequences: Treatment plans are no longer “one-size-fits-all”; they are adjusted based on your specific disease biology, previous treatment history, and physical fitness.
Selecting ARPI Treatment Beyond Simple Age Metrics
Treating metastatic castration-sensitive prostate cancer (mCSPC) now involves more than simple androgen deprivation therapy (ADT). Faculty at the OncLive scientific interchange emphasized that selecting an ARPI—such as abiraterone—requires a sophisticated assessment of comorbidities, cognitive effects, and potential drug interactions.
According to the STOPCAP meta-analysis, age alone is not a sufficient metric for treatment intensity. Experts like Watts noted that the biological range among 75-year-olds is vast, necessitating a move away from rigid age-based cutoffs toward individual clinical assessments.
Molecular selection is further refining these choices. The TALAPRO-3 trial (NCT04821622) demonstrated that combining talazoparib with enzalutamide significantly improves radiographic progression-free survival (rPFS) in patients with homologous recombination repair (HRR) gene alterations (HR, 0.481; P < .0001). However, enthusiasm remains tempered regarding other combinations, such as capivasertib plus abiraterone, where the CAPItello-281 trial showed more modest gains in rPFS for PTEN-deficient disease.
Using Triplet Therapies for High-Volume Disease
The use of docetaxel-based “triplet” therapies—combining ADT, an ARPI, and chemotherapy—is generally reserved for younger, fitter patients with high-volume or visceral disease. Faculty estimates suggest this approach applies to roughly 30% of patients in specialized practices.
Despite the survival benefits shown in the ARASENS trial (NCT02799602) for darolutamide-based triplets (HR, 0.68), clinicians noted a critical evidence gap: there are no direct, head-to-head randomized trials comparing these triplets against doublets containing newer-generation ARPIs.
“The triplets with chemo have not been shown to be better than a doublet with an ARPI,” Gartrell said.
| Trial | Combination | Primary Metric | Outcome (HR) |
|---|---|---|---|
| ARASENS | Darolutamide + ADT + Docetaxel | Overall Survival | 0.68 |
| TALAPRO-3 | Talazoparib + Enzalutamide | rPFS | 0.481 |
| CAPItello-281 | Capivasertib + Abiraterone | rPFS | 0.81 |
Balancing Pluvicto Adoption with Marrow Toxicity Risks
The integration of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) has created a strategic divide among oncologists. While some favor early adoption to ensure treatment occurs before resistance develops, others, including Dallos and Zhu, caution against the potential for cumulative marrow toxicity.
This concern is particularly relevant for patients who may live for several years. The PSMAfore trial (NCT04689828) results, which showed a median overall survival of 24.48 months for radioligand therapy versus 23.13 months for an ARPI change, show that patient preference and quality-of-life considerations matter when deciding when to introduce these advanced agents.
Risks and Access Barriers for Radioligand Therapy
Advanced prostate cancer therapies carry significant risks, including bone marrow suppression, fatigue, and potential cardiovascular or cognitive side effects. Patients with limited bone marrow reserve or those living in environments where radiation-safety protocols—such as specialized waste disposal or distance requirements—cannot be maintained may not be candidates for radioligand therapy.
Experts highlighted that the requirement for outpatient initiation, caregiver support, and health literacy can create unequal access, particularly for patients in multigenerational households or nursing facilities. As the field advances, the focus must remain on identifying therapies that are not only effective but also tolerable and accessible within the realities of a patient’s daily life.
“We need to have drugs that are better tolerated, and I think logistics are really important,” Gartrell said.
